Sign up to save your podcasts
Or
Share part 1: CNV and Anti-VEGF Therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
part 1: CNV and Anti-VEGF Therapy
Subject: part 1: CNV and Anti-VEGF Therapy Paper Discussed: Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology, June 2005, 112(6) p1035-47 Guest: Philip J. Rosenfeld, M.D., Ph.D. Associate Professor of Ophthalmology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida
View all episodes
By [email protected]Subject: part 1: CNV and Anti-VEGF Therapy Paper Discussed: Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology, June 2005, 112(6) p1035-47 Guest: Philip J. Rosenfeld, M.D., Ph.D. Associate Professor of Ophthalmology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida